Scientific responses were less impressive: only one individual achieved an ACR 70 response and another one an ACR 50 response
Scientific responses were less impressive: only one individual achieved an ACR 70 response and another one an ACR 50 response. by Rose and colleagues [2] were followed by the identification of numerous self-antigens that were recognized by autoantibodies. Antibodies to different autoantigens have remained one of the most important diagnostic assessments in clinical immunology. In some diseases, these antibodies have been directly implicated in tissue damage. It is, Rabbit Polyclonal to MINPP1 therefore, not surprising that humoral autoimmunity was at center stage in the 1960s and 1970s and that various treatment methods were designed to interfere specifically with autoantibody production or to remove autoantibodies from your blood circulation. Plasmapheresis was explored in the treatment of a variety of autoimmune syndromes, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and vasculitic syndromes. Plasmapheresis still has an accepted role in thrombotic thrombocytopenic purpura and cryoglobulinemia; however, in other chronic inflammatory diseases, plasmapheresis has had disappointing results. After 1980, treatment strategies no longer focused on the LY2228820 (Ralimetinib) B cell and the removal of autoantibodies but, rather, focused on effector mechanisms of macrophages and the cytokines that are produced in inflammatory responses. Thus, the success of recent pilot studies that explored B-cell depletion as a therapeutic strategy came unexpectedly and has renewed desire for reconsidering the role of the LY2228820 (Ralimetinib) B cell in these diseases [3,4]. == A new therapeutic strategy targeting CD20+B cells == All pilot studies of B-cell-depleting treatments have targeted the CD20 antigen using a chimeric mouse/human antibody, rituximab. Expression of CD20 is restricted to B cells from your pre-B-cell stage to the immunoblast stage [5]. Lymphoid precursors and plasma cells are spared in CD20-directed depletion. CD20 is not shed from your cell surface and does not internalize upon antibody binding [6]. Rituximab binds match and induces antibody-dependent cellular cytotoxicity, effectively depleting CD20-expressing cells. In addition, signaling via CD20 appears to activate proapoptotic pathways, further increasing the antibody’s depleting activity [7]. Rituximab has been used in the treatment of B-cell non-Hodgkin’s lymphoma as a single agent as well as in combination therapy, emphasizing its high B-cell-depleting potency [8]. In patients with lymphoma, rituximab infusion is frequently associated with a cytokine-release syndrome that probably results from CD20-mediated activation of tumor cells [9]. B-cell levels slowly recover over a period of approximately 6 months. Despite B-cell depletion, immunoglobulin levels are usually managed, possibly as a consequence of plasma cells being spared. == B-cell depletion in antibody-mediated diseases == It is understandable that rituximab has been most frequently explored in autoimmune cytopenias, a disease group that is clearly linked to the function of pathogenic autoantibodies. The best response rates were found for hemolytic anemia in chilly agglutinin disease, approaching 85% in one prospective study [10,11]. In other autoimmune cytopenias, such as other forms of hemolytic anemia or chronic autoimmune thrombocytopenia, response rates are lower and range from 30 to 50% [12-14]. These data confirm that, at least in some patients, plasma cells are not sufficient to maintain autoantibody levels and that continuous B-cell recruitment and activation are necessary to maintain autoantibody production. Some of the treated patients relapsed after the repopulation of B cells, consistent with the model that this breakdown of self-tolerance and the production of autoantibodies reflect a LY2228820 (Ralimetinib) defect in T-cell biology and not a primary B-cell dysfunction. However, some patients have sustained remissions, suggesting that this depletion of autoimmune memory B cells can have a long-lasting impact. Loss of B-cell memory function has also been pinpointed as a cause of severe side effects in anti-CD20-directed therapy. Patients with B-cell lymphoma who received anti-CD20 antibody treatment experienced reactivated hepatitis B and parvovirus contamination [15-17]. This is of particular concern in patients with hepatitis-C-associated mixed cryoglobulinemia. Preliminary data support the notion that the treatment is safe in these patients; however, larger studies with careful monitoring of hepatic end result are awaited. A trial to be sponsored by the US National Institutes of Health is in the planning stage. Although autoantibodies in autoimmune cytopenias and some other diseases, such as pemphigus and myasthenia gravis, LY2228820 (Ralimetinib) have a direct role in tissue injury through the acknowledgement of their antigen, their pathogenic functions in diseases such as Wegener’s granulomatosis.